Clinical Trial: Pasireotide Treatment for Neuroendocrine Tumor
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
Brief Summary: Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.
Detailed Summary:
Sponsor: University of Maryland
Current Primary Outcome: Hypoglycemia [ Time Frame: up to 12 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University of Maryland
Dates:
Date Received: May 16, 2016
Date Started: April 2016
Date Completion:
Last Updated: June 6, 2016
Last Verified: June 2016